PAPERS, ABSTRACTS, CASE REPORTS, LECTURE VIDEOS & SLIDES BY DR. BOB

______________________________________________________________________

acrobatreaderAll articles, case reports, and slides from lectures are available in Adobe Acrobat (PDF) format.

___________________________________________________

Videos of Lectures Now Available Online!

Click here to watch our lectures online

Papers By Dr. Bob

doc_iconDr. Bob’s Three-Pronged Protocol for Treating Metastatic, Advanced, High Risk and/Or Recurrent Prostate Cancer (11/2008)

doc_iconNew! Dr. Bob’s treatments and insights regarding Prostate Cancer (PAACT newsletter, 12/2013)

doc_icon     New!  Challenging PC Treatment Biases – Is Nothing Sacred? – Part I (PAACT newsletter, 3/2014)

doc_iconHigh-Dose Testosterone & Prostate Cancer : Wait until you read this update, September 1, 2009 – (9/1/2009)

Also see:
High-Dose Testosterone Replacement Therapy and Prostate Cancer
TRT Case Reports: High Dose Testosterone Replacement Therapy (TRT) and Prostate Cancer (CaP)

doc_iconTRT Case Reports: High-Dose Testosterone Replacement Therapy (TRT) and Prostate Cancer (CaP) (updated 05/2009)

Also see:
High-Dose Testosterone & Prostate Cancer : Wait until you read this update, September 1, 2009
High-Dose Testosterone Replacement Therapy and Prostate Cancer

doc_iconAntiangiogenic Cocktail (AAC) (8/2008), formerly “LEUKINE (GM-CSF) and REVLIMID, the Second Generation THALIDOMIDE Product” (updated 2/4/2008; originally   written 09/2006)

doc_iconPrimary Triple Androgen Blockade (TAB) Followed by Finasteride Maintenance (FM) for Clinically Localized Prostate Cancer (CL-PC): Long Term Follow-up and Quality of Life (QOL) – (2005 ASCO Prostate Cancer Symposium abstract) – co-authored with S. Tucker & J.N. Roundy

doc_iconTriple Hormone Blockade® Update: The Demise of the (Fool’s) Gold Standard; The Rise of the “Platinum and Diamond Standard”; Peer Recognition from the Multidisciplinary Prostate Cancer Conference, Orlando, Florida, February 2005, and the First International Conference on IAB, London, England, March 2005 (last updated 6/12/2008; originally written 02/2006)

doc_iconCompassionate Oncology’s Latest Three-Pronged Approach Patient Case Studies – presented at the Prostate Forum of OC Lecture on June 23, 2011, Fullerton CA

doc_iconTestosterone Replacement in Prostate Cancer Survivors with Hypogonadal Symptoms – coauthored with Tanya Dorff, Steven Tucker,  James Symanowski and Nicholas Vogelzang (British Journal of Urology International, May 2010; also published early online 11/2009)

doc_iconTaxotere Plus Avastin: Antiangiogenic Proof of Principle
(4/2008)

doc_iconHormone Refractory Prostate Cancer
(08/2004)

doc_iconTreatment of Localized Prostate Cancer With Intermittent Triple Androgen Blockade: Preliminary Results in 110 Consecutive Patients (2001)

doc_iconHormone Blockade as the Sole Treatment of Clinical Stages T1-T3 Prostate Cancer: Experience in 100 Patients (2000 ASCO Annual Meeting abstract)

doc_iconLow-Dose Single Agent Weekly Docetaxel (Taxotere) is Effective and Well Tolerated in Elderly Men with Prostate Cancer (2001 ASCO Annual Meeting abstract) – co-authored with M. Scholz, B. Guess, F. Barrios, & S. Strum

doc_iconIntermittent Hormone Blockade for Localized Prostate Cancer (2001 ASCO Annual Meeting abstract) – co-authored with S. Tucker

doc_iconFive-year Follow-up of Intermittent Triple Androgen Blockade (TAB) for Clinically Localized Prostate Cancer (PC): Prognostic Features and Preliminary Patterns of Failure – (2002 ASCO Annual Meeting abstract) – co-authored with S. Tucker

doc_iconAt What PSA Level Should Cycle Two of Hormone Blockade (HB) Commence in Men who Refuse Local Treatment for Prostate Cancer (CaP) and are Treated with Intermittent Androgen Blockade (IAB)? – (2002 ASCO Annual Meeting abstract) – co-authored with S. Tucker

doc_iconLow and Intermediate Risk Early Prostate Cancer (PC) Managed with Triple Androgen Blockade (TAB) (2003 ASCO Annual Meeting abstract)  – co-authored with S. Tucker

doc_icon

Primary Intermittent Chemo-Hormonal Therapy (CHT) for High Risk Locally Advanced (LAPC) orMetastatic Prostate Cancer (MPC): Preliminary Results and Quality of Life (QOL) – (2005 ASCO Annual Meeting abstract)  – co-authored with S. Tucker

doc_icon

High-Dose Testosterone Replacement Therapy and Prostate Cancer
(11/2006),

Also see:
High-Dose Testosterone & Prostate Cancer : Wait until you read this update, September 1, 2009
TRT Case Reports: High Dose Testosterone Replacement Therapy (TRT) and Prostate Cancer (CaP)

doc_iconProscar Greetings On Father’s Day: 2008 Update (last updated 6/25/08; originally written 06/1997)

doc_iconI Am The Only One You Are Afraid To Believe
(01/1999)

doc_iconHormone Blockade; Continuous, Intermittent, or ?
formerly, “Dr. Bob’s Approach,” (03/06)

doc_iconPotpourri of Prostate Pearls and Insights

(2007)

doc_iconStatin Drugs and Advanced Risk of Prostate Cancer
(01/2007)

doc_iconTestosterone Levels And Prostate Cancer — The Higher, The Better?
(01/2003)

doc_iconHigh-Dose Testosterone Replacement Therapy
(06/2004)

doc_iconTestosterone ASCO Abstract (Phase I trial of exogenous testosterone (T) for the treatment of castrate metastatic prostate cancer (PC) – Morris MJ et. al. (6/2004)), Discussion by Robert L. Leibowitz, MD 05/2004

doc_iconThe Emperor’s New Clothes or “The Platinum And Diamond Standard”
(04/2004),

doc_iconIntermittent Androgen Blockade (Formerly “The Future Is Now!!” – Part II)
(04/2004)

doc_iconProstate “Pearls”
(04/2004)

doc_iconThe Will Rogers Phenomenon
(04/2004)

doc_iconEarly Hormonal Therapy Works Ridiculously Well
(10/2003)

doc_iconCelebrex, and Anti-Cancer Activity
(02/2007)

doc_icon“PCAAC” Prostate Cancer Antiangiogenic Cocktail
(09/2002)

doc_icon“The Facts, Doc, Just The Facts”
(04/2004)

doc_iconDawning Of The Age Of Angiogenesis
(04/2004)

doc_iconThe Capitulation Of Radiation Therapy Has Begun
(04/2004)

doc_iconAngiostatin And Why Local Therapy Fails To Cure So Many Men (Formerly “The Transitional Zone Era”) (04/2004)

doc_iconPrimary Triple Androgen Blockade® (TAB) followed by Finasteride Maintenance® (FM) for clinically localized prostate cancer (CL-PC): Ten-year follow-up – coauthored with Nathan Roundy and Jeffrey Turner (Journal of Clinical Oncology, May 2011)

doc_iconHormone Blockade Versus Radical Local Therapies – And The Winner Is….
(11/2002)

doc_iconSoy and Prostate Cancer
(10/2007)

doc_iconBisphosphonates and Osteonecrosis of the Maxilla and/or Mandible (Jaw Bones)
(10/2005)

doc_iconAredia Monotherapy to Control Metastatic, Hormone Refractory Prostate Cancer for more than Six Years (11/2006)

doc_iconThe Risk of Thrombosis (Blood Clots) with the use of Thalidomide and/or Revlimid  (02/2007)

doc_iconInterferon and Anti-angiogenesis
(6/2007)

doc_iconCelebrex, a Cox-2 Inhibtor: Off Label Use for Treating Prostate and Other Cancers  (12/2006)

doc_iconDecember 2001 National Cancer Institute Article (Treatment Options)
(01/2002)

doc_iconDr. Bob’s Recommended Vitamin List
(10/2005)

doc_iconShingles; Vaccine and Post Shingles Pain
(04/2009)

______________________________________________________________________

Slide Presentations From Lectures Given By Dr. Bob

All presentations are available on DVD.  For more information click here.

Dr. Bob’s Three-Pronged Approach for
Treating High Risk Disease
and Associated PC Pearls of Wisdom (2009)
Robert L. Leibowitz MD
Presentation sponsored by the Wellness Community, Westlake Village, CA

Conquering/Controlling/Taming Advanced Prostate Cancer and Proving how to Successfully Live with Advanced Prostate Cancer (2007)
Robert L. Leibowitz MD
Presentation sponsored by the Prostate Forum of Fullerton, Fullerton, CA
(an US-TOO chapter)